Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.